By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares tumbled as much as 20% ...

Chief Executive Officer Mike Doustdar warned, “People should expect that it goes down before it comes back up,” citing pressure from significantly lower US pricing on its blockbuster weight-loss drug ...

Shares in the Danish pharmaceuticals group Novo Nordisk plunged Wednesday after the maker of Ozempic and Wegovy anti-obesity ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares plunged as much as 20% ...

COPENHAGEN, Feb 4 () - Novo Nordisk CEO Mike ​Doustdar said on ‌Wednesday that the price reductions ‌for its obesity drug ...

Novo Nordisk expects a decline in sales of up to 13 per cent this year as the Danish drugmaker competes in an increasingly crowded obesity-treatment market and faces pressure on the pricing of its ...

The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.

European shares were muted on Wednesday as losses in Novo Nordisk offset strength in energy stocks, with investors also tracking software shares and awaiting a key inflation report.

Novo's warning ends a years-long run of double-digit percentage gains in profits and sales since the launch of Wegovy in June ...

Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, has warned that profits and sales could fall by as much as 13 ...

Novo Nordisk A/S faces a margin crisis as oral Wegovy hits injectable profits. Click for this post-earnings update and see ...

Novo Nordisk's stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects ...